ERBB2 H878Y

CI-VAR-00001942Explore in graph →NP_001276866.1:p.His878TyrNM_001289937.1:c.2632C>TCIViC 874

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
ERBB2 H878Y	Trastuzumab Deruxtecan	Predictive	C	Supports Sensitivity Response	1	submitted	EID12529 The authors report a case series where one patient with lung adenocarcinoma harbored ERBB2 variant H878Y (exon 21). Case 2, a 59-year-old male, received Trastuzumab deruxtecan (T-DXd) (5.0 mg/kg once … (full text at CIViC) PMID 40873587 · Meng et al., 2025 · Open in CIViC	civic
Malignant Neoplasm1
ERBB2 H878Y	Lapatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1989 Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.